Coverage Initiated on Telemedicine Firm in 'Strong Position for Long-Term Growth'
Source: Streetwise Reports  (9/30/20)
The investment thesis for CloudMD Software & Services is presented in a Mackie Research Capital Corp. report. More >

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
Source: Streetwise Reports  (9/30/20)
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. More >

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (9/30/20)
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. More >

Genetron Receives FDA Breakthrough Approval for Hepatocellular Carcinoma Detection Device
Source: Streetwise Reports  (9/30/20)
Genetron Holdings Ltd. shares traded 25% higher after the company reported it has received Breakthrough Device Designation from the FDA for its blood-based next-generation sequencing test for early hepatocellular carcinoma detection. More >

Aptorum Shares Skyrocket Upon Launching Infectious Disease Liquid Biopsy Unit
Source: Streetwise Reports  (9/29/20)
Shares of Aptorum Group Ltd. traded nearly 300% higher after the company reported it launched an infectious disease liquid biopsy start-up subsidiary. More >

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test
Source: Streetwise Reports  (9/28/20)
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. More >

Owens & Minor Shares Climb 50% after Raising FY/20 Earnings Guidance by 66%
Source: Streetwise Reports  (9/24/20)
Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021. More >

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
Source: Streetwise Reports  (9/23/20)
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. More >

California-Based Biotech Receives COVID-19 Trial Clearance
Source: Streetwise Reports  (9/23/20)
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. More >

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens
Source: Streetwise Reports  (9/23/20)
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. More >

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study
Source: Streetwise Reports  (9/22/20)
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. More >

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
Source: Streetwise Reports  (9/21/20)
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. More >

Biopharma Advances Development of Psilocybin-Based Therapeutics
Source: Streetwise Reports  (9/21/20)
Revive Therapeutics provides an update on its psychedelics therapeutics programs. More >

Pharma Greenlighted to Continue Multinational COVID-19 Study
Source: Streetwise Reports  (9/18/20)
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. More >

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19
Source: Streetwise Reports  (9/17/20)
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. More >

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial
Source: Streetwise Reports  (9/17/20)
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. More >

Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug
Source: Streetwise Reports  (9/16/20)
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. More >

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial
Source: Streetwise Reports  (9/16/20)
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. More >

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results
Source: Streetwise Reports  (9/15/20)
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. More >

Amwell, with $100 Million Google Investment and Access to 80 Million Patients, Expected to Begin Trading on NYSE Sept. 17
Source: Streetwise Reports  (9/15/20)
Virtual care company American Well Corp., which operates under the name Amwell®, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL. More >

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer
Source: Streetwise Reports  (9/14/20)
Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash. More >

As COVID Is Turbocharging the Adoption of TeleHealth, Small Cap Is Growing Exponentially
Source: Streetwise Reports  (9/9/20)
All three brokerage firms that cover the rapidly expanding CloudMD Software & Services rate the company a Speculative Buy, and now the company has gained a toehold in the U.S. More >

Life Sciences Company Posts Record Q3 Revenue Due to Successful Recurring Purchase Model
Source: Streetwise Reports  (9/9/20)
Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels. More >

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings
Source: Streetwise Reports  (9/9/20)
Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy. More >

U.S. Medical Device Firm to Acquire Developer of Dissection Stent
Source: Streetwise Reports  (9/9/20)
The specifics of the deal and the next steps for CryoLife are presented in a Ladenburg Thalmann report. More >